The global molecular diagnostics market is projected to grow with rising technological developments in molecular diagnostic techniques. These advancements are intended to offer higher accuracy, cost-effectiveness, and portability which further drives the market. This information was published by Fortune Business Insights in a report, titled “Molecular Diagnostics Market Size, Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025” offering insights on factors influencing growth. The global market covered a value of US$ 8012.7 Mn in the year 2017 and is projected to reach US$ 13873.6 Mn by 2025. As per the report, the global market is expected to garner a healthy CAGR of 7.1% throughout the forecast period.
some of the key players in the global Molecular Diagnostics Market:
- bioMérieux SA.
- Grifols, S.A.
- Hologic Inc.
- Novartis AG
- Siemens Healthcare GmbH
- Hoffmann-La Roche Ltd.
Infectious Diseases: The Largest Growing Segment Among Other Applications
Among applications, infectious diseases segment is expected to account for a majority of share in the global molecular diagnostic market. The scope of this segment is increasing owing to the rising number of patients suffering from infections and microbial outbreaks. Moreover, the infectious diseases segment covered a share of 60% in the year 2017. Development of tests for several diseases and rising awareness about the benefits of adopting molecular diagnostic technologies may prevent the occurrence of infectious diseases. Global organizations such as World Bank and the World Health Organization (WHO) are planning to conduct awareness programs to increase the talent pool for molecular diagnostics. Adoption of molecular diagnostic systems is rising among end-users such as clinics, hospitals, emergency centers, and pathology labs.
North America Continues to Maintain Its Stronghold until 2025
“Well-established healthcare infrastructure, combined with the rising incidence of cancer is helping the market grow in North America,” stated a lead analyst at Fortune Business Insights. “Developed healthcare systems further helps in the easy availability and accessibility of advanced instruments such as molecular diagnostics. In 2017, this regional market was valued at US$ 3639.4 Mn and is likely to lead the global landscape through the forecast period. The rising collaborations and association between research hospitals and academic institutions encourages growth of the market in this region. Both the bodies are involving in continuous discussions for process improvements in molecular diagnosis. The market in Europe is also expected to witness considerable growth with growing emphasis on clinical microbiology and hospital research organizations. This is mainly done to increase the number of molecular diagnostic techniques. Rapidly developing healthcare infrastructure and rising investments in research and development activities are factors responsible for creating good growth opportunities.
More Trending Topics from Fortune Business Insights: